Characterization of endocytosis and exocytosis of cationic nanoparticles in airway epithelium cells

被引:96
作者
Dombu, Christophe Youta [1 ]
Kroubi, Maya [1 ]
Zibouche, Rima [1 ]
Matran, Regis [1 ]
Betbeder, Didier [1 ,2 ]
机构
[1] Univ Lille 2, Fac Med Pole Rech, Physiol Lab, IFR 114,EA 4483, F-59045 Lille, France
[2] Univ Artois, F-62030 Arras, France
关键词
INTRANASAL IMMUNIZATION; INTRACELLULAR FATE; SEMLIKI-FOREST; IN-VITRO; DELIVERY; PEPTIDE; ENTRY; THERAPEUTICS; COMBINATION; ABSORPTION;
D O I
10.1088/0957-4484/21/35/355102
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
A major challenge of drug delivery using colloids via the airway is to understand the mechanism implied in their interactions with epithelial cells. The purpose of this work was to characterize the process of endocytosis and exocytosis of cationic nanoparticles (NPs) made of maltodextrin which were developed as a delivery system for antigens in vaccine applications. Confocal microscopy demonstrated that these NP are rapidly endocytosed after as little as 3 min incubation, and that the endocytosis was also faster than NP binding since most of the NPs were found in the middle of the cells around the nuclei. A saturation limit was observed after a 40 min incubation, probably due to an equilibrium becoming established between endocytosis and exocytosis. Endocytosis was dramatically reduced at 4 degrees C compared with 37 degrees C, or by NaN3 treatment, both results suggesting an energy dependent process. Protamine pretreatment of the cells inhibited NPs uptake and we found that clathrin pathway is implied in their endocytosis. Cholesterol depletion increased NP uptake by 300% and this phenomenon was explained by the fact that cholesterol depletion totally blocked NP exocytosis. These results suggest that these cationic NPs interact with anionic sites, are quickly endocytosed via the clathrin pathway and that their exocytosis is cholesterol dependent, and are similar to those obtained in other studies with viruses such as influenza.
引用
收藏
页数:8
相关论文
共 39 条
[1]   Targeted delivery of nanoparticles for the treatment of lung diseases [J].
Azarmi, Shirzad ;
Roa, Wilson H. ;
Loebenberg, Raimar .
ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (08) :863-875
[2]   Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles [J].
Baudner, BC ;
Balland, O ;
Giuliani, MM ;
Von Hoegen, P ;
Rappuoli, R ;
Betbeder, D ;
Del Giudice, G .
INFECTION AND IMMUNITY, 2002, 70 (09) :4785-4790
[3]   Clathrin-coated pits: vive la difference? [J].
Benmerah, Alexandre ;
Lamaze, Christophe .
TRAFFIC, 2007, 8 (08) :970-982
[4]   The uptake and intracellular fate of PLGA nanoparticles in epithelial cells [J].
Cartiera, Malgorzata S. ;
Johnson, Katherine M. ;
Rajendran, Vanathy ;
Caplan, Michael J. ;
Saltzman, W. Mark .
BIOMATERIALS, 2009, 30 (14) :2790-2798
[5]   Effect of cholesterol depletion on exocytosis of alveolar type II cells [J].
Chintagari, Narendranath Reddy ;
Jin, Nili ;
Wang, Pengcheng ;
Narasaraju, Telugu Akula ;
Chen, Jiwang ;
Liu, Lin .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2006, 34 (06) :677-687
[6]   Barrier properties of mucus [J].
Cone, Richard A. .
ADVANCED DRUG DELIVERY REVIEWS, 2009, 61 (02) :75-85
[7]   Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans [J].
Console, S ;
Marty, C ;
García-Echeverría, C ;
Schwendener, R ;
Ballmer-Hofer, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (37) :35109-35114
[8]   Nanotechnology: Intelligent design to treat complex disease [J].
Couvreur, Patrick ;
Vauthier, Christine .
PHARMACEUTICAL RESEARCH, 2006, 23 (07) :1417-1450
[9]   Intranasal immunization with recombinant antigens associated with new cationic particles induces strong mucosal as well as systemic antibody and CTL responses [J].
Debin, A ;
Kravtzoff, R ;
Santiago, JV ;
Cazales, L ;
Sperandio, S ;
Melber, K ;
Janowicz, Z ;
Betbeder, D ;
Moynier, M .
VACCINE, 2002, 20 (21-22) :2752-2763
[10]   A combination of interleukin-2 and 60 nm cationic supramolecular biovectors for the treatment of established tumours by subcutaneous or intranasal administration [J].
El Mir, S ;
Casanova, A ;
Betbeder, D ;
Triebel, F .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (08) :1053-1060